Canada-based Medicure Inc (TSXV:MPH)(OTC:MCUJF), a cardiovascular pharmaceutical company, has reported its financial results for the quarter ended 31 March 2020 on Tuesday.
The company reported total net revenue from the sale of products of USD3m during the first quarter of 2020, compared to USD4.9m in the year-ago period.
The firm posted net loss for the quarter ended 31 March 2020 at USD1.5m or USD0.14 per share compared to a net loss of USD2.8m or USD0.18 per share for the same period in 2019.
GSK wins European Commission approval for Shingrix prefilled syringe
Tri-City Cardiology adds new members to care team
GENinCode expands Mexico presence with CARDIO inCode-Score distribution agreement
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
InsiteOne agrees strategic partnerships with ASCEND Cardiovascular and Apollo Enterprise Imaging
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
LivaNova secures higher Medicare reimbursement for VNS Therapy procedures